The document provides an overview of biotechnology company Amgen, including its introduction, current management, awards won in 2016, top-selling drugs like Epogen and Neupogen, and controversial issues. It discusses Amgen's collaborations with NASA on bone loss research and its strengths such as its large sales profits and patent portfolio. It also lists some risks facing Amgen like competition and potential challenges to its intellectual property.